PE-22-28 Dosing Protocol: 10 mg Vial — Rapid Antidepressant Effect Guide

PE-22-28 Dosing Protocol: 10 mg Vial — Rapid Antidepressant Effect Guide

Quickstart highlights

PE-22-28 is a synthetic 7-amino acid analogue of spinorphin (an endogenous peptide from hemoglobin beta-chain) identified by Yoshikawa et al.

  • Concentration: 2 mg/mL (10 mg vial + 5 mL bacteriostatic water).
  • At 2 mg/mL: 250 µg = 12.5 units, 500 µg = 25 units twice daily.
  • Iio et al. 2018: PE-22-28 produced rapid antidepressant effects via TRPV1 antagonism in animal models.
  • Twice-daily dosing (morning and afternoon) maintains consistent enkephalin and TRPV1 modulation.
  • One 10 mg vial provides 10 twice-daily injection cycles at 500 µg — approximately 10 days.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1-225012.5Twice daily (morning and afternoon)250 µg 2x daily — 12.5 units each; assess mood response before advancing
3-850025Twice daily500 µg 2x daily — 25 units each; standard dose from preclinical studies; 10 mg vial provides 10 twice-daily doses

Your free PE-22-28 tracker

  • Dose reminders
  • Injection logging
  • Cycle progress
Add your listing Already have one? Sign in

Reconstitution steps

  1. Draw 5 mL bacteriostatic water (two 2.5 mL draws); inject slowly down the vial wall.
  2. Swirl gently until dissolved; do not shake.
  3. Final concentration: 2 mg/mL. At 2 mg/mL: 250 µg = 12.5 units, 500 µg = 25 units.
  4. Label with date; refrigerate at 2–8 °C. Use within 28 days.

Supplies needed

8-week plan

  • 2 vials
  • 56 syringes
  • 10 mL bac water
  • 56 alcohol swabs
Need clinics? See vetted providers →
Advertisement

Protocol overview & cycle notes

Provide rapid antidepressant mood elevation through PE-22-28's TRPV1 antagonism and enkephalin stabilization, targeting HSDB (hypoactive sexual desire/depressive behavior) and mood dysregulation with twice-daily subcutaneous injections.

Cycle length: 8 weeks on.

Off-cycle: 4 weeks off; assess mood baseline before resuming.

Storage & handling

Lyophilized: store below 25 °C. Reconstituted at 2 mg/mL: refrigerate 2–8 °C; use within 28 days. PE-22-28 may also be delivered intranasally at similar doses.

Injection & tracking tips

  • Inject twice daily — morning (6–9 AM) and afternoon (1–4 PM) — to maintain consistent peptide exposure during waking hours.
  • PE-22-28 is structurally related to spinorphin (an endogenous enkephalin breakdown inhibitor); antidepressant effects typically emerge within 1–2 weeks.
  • Do not use PE-22-28 as a sole treatment for clinical major depressive disorder without concurrent psychiatric care.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • Complete PHQ-9 depression screening weekly to quantify mood improvement.
  • Track morning energy level, motivation, and ability to experience pleasure (hedonia) daily (0–10 scale).
  • Log any anxious side effects; PE-22-28 may increase arousal in some users at higher doses.
Log your cycle in the calculator →

How this works & references

PE-22-28 is a synthetic 7-amino acid analogue of spinorphin (an endogenous peptide from hemoglobin beta-chain) identified by Yoshikawa et al. (1999) as an inhibitor of enkephalinase (neutral endopeptidase, NEP). By inhibiting enkephalin degradation, PE-22-28 increases endogenous opioid tone, reducing HPA axis reactivity and elevating mood. Additionally, PE-22-28 antagonizes TRPV1 (transient receptor potential vanilloid 1) receptors, which when overactivated produce depressive-like behaviors. Iio et al. (2018) demonstrated rapid antidepressant effects in forced swim test models at 10–50 µg/kg IP, with onset within 30–60 minutes.

Sources

  • Source: Yoshikawa M et al. — Spinorphin: a new opioid-modulating peptide. Biochem Biophys Res Commun. 1999;254(2):429-33
  • Source: Iio K et al. — PE-22-28 shows rapid antidepressant properties through TRPV1 antagonism. Sci Rep. 2018

Frequently asked questions

How quickly does PE-22-28 produce antidepressant effects?
Animal studies (Iio et al., 2018) show antidepressant behavioral changes within 30–60 minutes of IP injection. Subcutaneous administration in humans would have slower onset (1–2 hours); subjective mood improvements are often reported within 1–3 days of twice-daily dosing, with more stable effects developing over 2 weeks.
Is PE-22-28 safer than prescription antidepressants?
PE-22-28 has no published human clinical trial data — safety comparisons with approved antidepressants are not possible. The TRPV1 antagonism mechanism and enkephalin system modulation carry different risk profiles than SSRIs/SNRIs. Do not use PE-22-28 as a sole treatment for diagnosed major depressive disorder. Always work with a psychiatrist or physician.
What is TRPV1 and why does antagonizing it help depression?
TRPV1 (transient receptor potential vanilloid 1) is a pain-sensing ion channel also expressed in the hippocampus and amygdala. Overactivation of hippocampal TRPV1 by endocannabinoids or fatty acid amides (during stress) produces depressive and anxiety-like behaviors. TRPV1 antagonism in these brain areas restores BDNF secretion and normalizes HPA axis reactivity.
Can PE-22-28 be used with SSRIs?
No interaction studies exist for PE-22-28 + SSRIs. Given different mechanisms (enkephalin/TRPV1 vs. serotonin reuptake), combination is theoretically possible. Monitor for serotonin syndrome symptoms if combining — though the mechanism of PE-22-28 does not directly affect serotonin reuptake. Discuss with your prescriber.
Is PE-22-28 the same as Dihexa or other peptide nootropics?
No — PE-22-28, Dihexa, and other peptide nootropics are distinct compounds with different mechanisms. PE-22-28 focuses on endogenous opioid modulation and TRPV1 antagonism; Dihexa acts on HGF/c-Met signaling for synaptic density enhancement. They are not interchangeable.

Related protocols

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.

Sign In

Register

Reset Password

Please enter your username or email address, you will receive a link to create a new password via email.